HIV Infections Clinical Trial
Official title:
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
A randomized clinical trial evaluating the reduction of HIV risk behaviors and drug use when providing integrated behavioral drug and HIV risk reduction counseling (BDRC) along with methadone maintenance treatment in Wuhan, China
This project is a supplement to a parent grant, Drug Counseling and Abstinence-Contingent
Take-Home Buprenorphine in Malaysia. The specific aims of the parent grant include evaluating
whether the relatively minimal counseling and other services provided with standard
buprenorphine maintenance treatment (Standard BUP) is sufficient or whether one or a
combination of two enhanced behavioral treatments--behavioral drug and HIV risk reduction
counseling (BDRC) or abstinence-contingent take-home buprenorphine (ACB)—improve its efficacy
(Specific Aim 1) and are cost-effective, with regard to the direct economic costs of
providing the treatments (Specific Aim 2) and also to provide training and mentoring in drug
abuse treatment and HIV prevention research to clinical researchers and clinical training for
health professionals in Malaysia (Specific Aim 4). BDRC utilizes short-term behavioral
contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can
be provided by nurses and medical assistants available in medical settings in developing
countries.
The specific aims of the proposed study are consistent with the specific aims of the parent
grant and include evaluating in a pilot, randomized clinical trial in a methadone treatment
program in Wuhan, China, the feasibility and potential efficacy for reducing illicit drug use
and HIV risk behaviors of BDRC when combined with standard methadone treatment services
(Standard Methadone) compared to Standard Methadone only (Specific Aim 1 of the proposed
study). Additional Specific Aims of the proposed study include developing estimates of the
treatment costs and cost-effectiveness of Standard Methadone and BDRC (Specific Aim 2 of the
proposes study), and providing training and mentoring in drug abuse treatment and HIV
prevention research to clinical researchers an clinical training for health professionals in
China (Specific Aim 3 of the proposed study).
Specific aims of the China project:
1. Conduct a preliminary evaluation of the feasibility, acceptability, and preliminary
efficacy for increasing treatment retention and reducing drug use and HIV risk behaviors
of Behavioral Drug and HIV Risk Reduction Counseling (BDRC) when combined with Standard
Methadone, in comparison to Standard Methadone, among opiate dependent treatment seeking
volunteers admitted to the Wuhan Methadone Clinic.
2. Develop estimates of the costs and cost-effectiveness of Standard Methadone and BDRC.
3. Train and provide ongoing clinical supervision to a core group of 10 drug counseling
staff and provide additional mentoring in drug abuse and HIV risk reduction research to
investigators in China.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |